In­side Bio­gen's scram­ble to sell Aduhelm: Project 'Javelin' and pres­sure to ID as many pa­tients as pos­si­ble

In an­tic­i­pa­tion of Aduhelm’s ap­proval for Alzheimer’s in June, Bio­gen em­ploy­ees were di­rect­ed to iden­ti­fy and guar­an­tee treat­ment cen­ters would ad­min­is­ter the drug through a pro­gram called “Javelin,” a se­nior Bio­gen em­ploy­ee told End­points News.

The pro­gram iden­ti­fied about 800 cen­ters for use, he said, and Bio­gen now pays for the use of bioas­says to iden­ti­fy be­ta amy­loid in po­ten­tial pa­tients hav­ing un­der­gone a lum­bar punc­ture pro­ce­dure, the em­ploy­ee said — and one cen­ter prepar­ing to ad­min­is­ter the drug con­firmed its par­tic­i­pa­tion in the bioas­say pro­gram.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.